Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of COVID-19-Induced Acute Respiratory Distress: A Phase 2 Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells

Next Previous
Trial Profile

Treatment of COVID-19-Induced Acute Respiratory Distress: A Phase 2 Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PSC-04 (Primary)
  • Indications SARS-CoV-2 acute respiratory disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Sorrento Therapeutics

Most Recent Events

  • 14 Sep 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
  • 20 May 2021 According to a Sorrento Therapeutics media release, The patient enrollment (n=100, 33 placebo and 67 treated patients) is expected in three months from the date of first enrollment. This projected pace of enrollment is expected due to the extensive disease burden in Brazil. The company has partnership with a leading local clinical research organization (Synova Health), and existing relationships with high quality medical centers throughout the country.
  • 20 May 2021 According to a Sorrento Therapeutics media release, the enrollment of patients is anticipated to commence in June 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top